Eupraxia Pharmaceuticals (EPRX) Receivables (2022 - 2025)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Receivables of $1.4 million for Q4 2025, up 185.52% year-over-year from $486946.0 in Q4 2024, and up 185.52% quarter-over-quarter from $486946.0 in Q4 2024.
Eupraxia Pharmaceuticals (EPRX) Receivables (2022 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Receivables for 4 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables rose 185.52% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (up 185.52% YoY), while the FY2025 annual figure was $1.4 million, up 185.52% from the prior year.
- Receivables grew to $1.4 million in Q4 2025 per EPRX's latest filing, from $486946.0 in the prior quarter.
- Across five years, Receivables topped out at $1.4 million in Q4 2025 and bottomed at $103607.0 in Q4 2022.
- Historically, Receivables has averaged $581308.8 across 4 years, with a median of $415653.5 in 2023.
- Annual changes were most pronounced in 2023 — Receivables jumped 232.37% — and 2024, when it jumped 41.41%.
- Eupraxia Pharmaceuticals' Receivables stood at $103607.0 in 2022, then surged by 232.37% to $344361.0 in 2023, then surged by 41.41% to $486946.0 in 2024, then jumped by 185.52% to $1.4 million in 2025.
- Business Quant data shows EPRX's Receivables at $1.4 million in Q4 2025, $486946.0 in Q4 2024, and $344361.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 486,946.00 |
| Dec 31, 2023 | 344,361.00 |
| Dec 31, 2022 | 103,607.00 |